NetworkNewsBreaks – ViewRay, Inc. (NASDAQ: VRAY) Covered at Aegis with ‘Buy’ Rating, $11 PT
Aegis Capital Corp. recently initiated coverage of ViewRay (NASDAQ: VRAY), issuing a 'Buy' rating and $11 price target on the company's stock. ViewRay’s MRIdian® radiation therapy system is designed to address key restrictions of current external-beam radiation therapy technologies, and is the first of its kind to use real-time imaging that visibly defines the targeted tumor from the surrounding soft tissue and other critical organs. The company believes this will greatly improve the safety and efficacy of radiation therapy, leading to better results for patients. Most recently, the company announced that the Edogawa Hospital in Tokyo, Japan, purchased the system…